The Federal Trade Commission issued a Second Request for additional information and documentary materials regarding the proposed merger between MiMedx Group, Inc. and Sanara MedTech Inc. This action extends the Hart-Scott-Rodino antitrust waiting period until 30 days after substantial compliance with the request. The transaction remains subject to regulatory approval and other closing conditions. MiMedx operates in the regenerative medicine sector, developing products for wound healing and surgical applications.
